A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer Journal Article
| Authors: | Rugo, H. S.; Jo Chien, A.; Franco, S. X.; Stopeck, A. T.; Glencer, A.; Lahiri, S.; Arbushites, M. C.; Scott, J.; Park, J. W.; Hudis, C.; Nulsen, B.; Dickler, M. N. |
| Article Title: | A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer |
| Abstract: | Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)-targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive clinical benefit from this combination. The purpose of this single-arm phase II study was to determine the efficacy and safety of the dual-targeting combination of lapatinib and bevacizumab. Women with HER2-overexpressing advanced breast cancer received 1,500 mg oral lapatinib daily plus 10 mg/kg IV bevacizumab every 2 weeks. The primary endpoint was progression-free survival (PFS) at week 12; secondary endpoints included overall tumor response rate (ORR), clinical benefit rate (CBR), duration of response, time-to-response, PFS, and safety. Circulating tumor cells (CTC) and circulating endothelial cells (CEC) were measured at baseline and during study treatment as potential response markers. Fifty-two patients with stage IV disease were enrolled. The 12-week investigator-assessed PFS rate was 69.2% (95% confidence interval [CI]: 54.9, 81.3). Median PFS was 24.7 weeks (95% CI: 20.4, 35.1), and the CBR was 30.8% (95% CI: 18.7, 45.1). Of 45 patients with measurable disease, 6 were determined to have a partial response per Response Evaluation Criteria in Solid Tumors (ORR: 13.3%; 95% CI: 5.1, 26.8). The most common adverse events (AEs) included diarrhea, rash, and fatigue; most of these were either grade 1 or 2. Clinical responses were correlated with decreases in CTC and CEC. Lapatinib plus bevacizumab was active in patients with HER2-overexpressing breast cancer. The AE profile of the combination was consistent with the known profiles for these agents. © 2011 The Author(s). |
| Keywords: | adult; controlled study; treatment outcome; aged; disease-free survival; middle aged; major clinical study; fatigue; review; bevacizumab; diarrhea; drug dose reduction; drug efficacy; drug safety; drug withdrawal; gastrointestinal hemorrhage; heart left ventricle failure; hypertension; side effect; disease marker; anorexia; gene overexpression; progression free survival; drug eruption; phase 2 clinical trial; breast cancer; gene expression; anemia; nausea; antineoplastic combined chemotherapy protocols; proportional hazards models; epidermal growth factor receptor 2; breast neoplasms; endothelium cell; correlation analysis; multicenter study; cancer cell; drug response; neoplasm metastasis; targeted therapy; receptor, erbb-2; hyperbilirubinemia; headache; tyrosine kinase inhibitor; quinazolines; epistaxis; lapatinib; her2; hydronephrosis; vegf; gastritis; antibodies, monoclonal, humanized; clinical benefit rate; duration of response; time to response |
| Journal Title: | Breast Cancer Research and Treatment |
| Volume: | 134 |
| Issue: | 1 |
| ISSN: | 0167-6806 |
| Publisher: | Springer |
| Date Published: | 2012-07-01 |
| Start Page: | 13 |
| End Page: | 20 |
| Language: | English |
| DOI: | 10.1007/s10549-011-1918-z |
| PROVIDER: | scopus |
| PMCID: | PMC3397213 |
| PUBMED: | 22198412 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 August 2012" - "CODEN: BCTRD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work